Asacol tablets for Crohn's disease 400 mg from Japan

General information on Asacol tablets for Crohn's disease 400 mg from Japan

Package details: 100 tablets

Manufacturer: Zeria Pharmaceutical Co., Ltd., Japan

Active ingredient: mesalazine 400 mg (chemical formula C7H7NO3).

Medical effect: mesalazine is effective for mild to moderate Crohn’s disease. It blocks the synthesis of prostaglandins and leukotrienes, providing an anti-inflammatory effect. Mesalazine also helps to heal damaged sections of the intestine, reduces pain, and relieves intestinal bleeding.

Dosage and administration:

For adults, take 2 tablets 3 times a day. For children, take the drug 3 times a day at a rate of 40-60 mg of active substance per 1 kg of weight per day. Dosage can be adjusted by the consulting doctor.

Contraindications, precautions:

For pregnant women, the risks and benefits should be discussed with the consulting doctor before use. While using the medication, the breastfeeding should not be performed. Mesalazine is also contraindicated in the following individuals:

• patients with hypersensitivity to salicylates,
• patients with impaired liver and kidney function,
• patients with gastric ulcer,
• patients with duodenal ulcer.

How effective are Asacol tablets for Crohn's disease 400 mg from Japan?

Japanese Asacol tablets for Crohn's disease 400 mg are effective in achieving remission in patients with Crohn's disease. Mesalazine reduces the number of immune and mast cells in the intestinal mucosa and, thus, relieves mucosal irritation and heals intestinal bleeding. With a mild form of Crohn's disease, it is sufficient to use only mesalazine for a long time. In addition, mesalazine increases the effectiveness of other drugs, such as azathioprine.

Who should use Asacol 400 mg Crohn's tablets from Japan?

Asacol tablets for Crohn's disease 400 mg from Japan are suitable for patients with mild to moderate form of Crohn's disease, especially for children. They relieve pain, accelerate the healing of the mucous membrane, relieve intestinal bleeding. Studies show particular efficacy of mesalazine for use in children from 6 years of age (H. Wiersma, J. C. Escher et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflammatory Bowel Diseases, 2004 Sep; 10 (5): 626-31).